A systematic review of cannabidiol trials in neurodevelopmental disorders

Key Findings:  This review of nine clinical trials that tested cannabidiol (CBD) for treating symptoms of neurodevelopmental disorders (attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), intellectual disability (ID), Tourette's syndrome (TS), and complex motor disorders (CMD) finds that the preliminary evidence is encouraging, but overall there is a lack of rigorous testing and overall inconclusive evidence for its use.

Type of Study:  Clinical Meta-analysis

Study Sample Size:  9

Study Result:  Positive

Study Location(s):  Australia

Year of Pub:  2023

Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Cannabidivarin (CBDV)

Phytocannabinoid Source:  Unspecified

Chemotype:  Chemotype III

Receptors Studied:  CB1, CB2

Ligands Studied:  GABA, Glutamate, Norepinephrine, Oxytocin, Serotonin, Glucocorticoid